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ABSTRACT
Objectives: Digoxin is a well-known probe for the activity of P-glycoprotein. The objective of
this work was to apply different methods for covariate selection in non-linear mixed effect models to
study the relationship between the pharmacokinetic parameters of digoxin and the genotype for two
major exons located on the MDR-1 gene coding for P-glycoprotein.
Methods: Thirty-two healthy volunteers were recruited in three pharmacokinetic drug interac-
tion studies. The data after a single oral administration of digoxin alone were pooled. All subjects
were genotyped for the MDR1 C3435T and G2677T/A genotypes. The concentration-time profile of
digoxin was established using 12 to 16 blood samples taken 15 minutes to 72 hours after administra-
tion.
We modelled the pharmacokinetics of digoxin using non-linear mixed effect models. Parameter
estimation was performed using the stochastic approximation EM method (SAEM). We used three
methods to select the covariate model: selection from a full model using Wald tests, forward inclusion
using the log-likelihood ratio test and model selection using the Bayesian Information Criteria.
Results: The three covariate inclusion methods led to the same final model. Carriers of two T
alleles for the C3435T polymorphism in exon 26 of MDR1 had a lower apparent volume of distribu-
tion than carriers of a C allele. The only other covariate effect was a shorter absorption time-lag in
women.
Conclusion: The apparent volume of distribution of digoxin is lower in TT subjects, probably
reflecting differences in bioavailability. Non-linear mixed effect models can be useful to detect the
influence of covariates on pharmacokinetic parameters.
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Introduction
Pharmacogenetics is a recent field of research investigating the variability in drug effect due to ge-
netic factors. Genetic variation occurs at many levels: drug absorption, distribution and metabolism,
receptors for drug action, and drug elimination. Single-Nucleotide Polymorphisms (SNPs) have been
identified which induce modifications of the pharmacokinetics (drug course through the body) or
pharmacodynamics (drug efficacy and safety). SNPs have namely been shown to modify bioavail-
ability [1, 4], decrease excretion [25] sometimes inducing severe toxicity [10] and have been linked to
drug efficacy [6, 13]. Thus, pharmacogenetics are the next step to provide individualised treatments.
The studies including pharmacogenetic data have become more numerous over the last few years.
In an overwhelming majority of these studies, non-compartmental analysis (NCA) is used to com-
pare pharmacokinetic measurements such as AUC or maximum concentration between groups. This
technique requires a large number of sampling points for every subject. On the other hand, mod-
elling approaches can take advantage of sparse individual designs and can be used in patients with
routine clinical data [26], but these more sophisticated approaches are seldom used. One issue with
these approaches is the method used for covariate selection and hypothesis testing, since detecting a
gene effect can be thought of as a model selection problem. A wide variety of approaches have been
proposed. The mainstream method consists in stepwise selection [23, 17], possibly following prior
screening of relevant candidate covariates. The criterion for model selection is usually the likelihood
ratio test, which is widely used to compare nested mixed effect models. Tests assessing the statistical
significance of the final parameters in the final model, such as the Wald test, can also be used as a
selection criterion [26]. Other criteria can be used in model selection, such as the Akaike (AIC) or
the Bayesian Information Criterion (BIC) [22]. Regardless of the method used, the clinical relevance
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is sometimes also assessed by examining the magnitude of the effects found.
In a previous paper, Verstuyft et al. estimated the AUC of digoxin, a probe for the activity of
P-glycoprotein, in healthy volunteers using non-compartmental analysis and showed an increase in
subjects carrying the TT genotype for the C3435T polymorphism of MDR-1 [38]. The objective of
the present paper was to reanalyse the data in [38] by a modelling approach, using three covariate
model selection methods: likelihood ratio tests, backwards selection from a full model using Wald
tests, which take into account potential correlations between covariates, and model selection using
the BIC, which considers all the potential models. A related problem in covariate selection is that
the false positive rate (type I error) of the tests has been shown to increase when the estimation
methods rely on linear approximations to the likelihood [7, 40]. In this work, we therefore use a
recent estimation method, the stochastic EM algorithm SAEM [20]. Although the three methods
can be applied with other estimation algorithms, SAEM allows estimation of the likelihood without
approximation, via stochastic simulation, and has been shown to have better statistical properties than
linearised methods [33].
Materials and methods
Data
Pharmacokinetic data was collected from 32 healthy volunteers included in three pharmacokinetic
interaction studies dealing with oral digoxin [38]. Seven subjects participated in a macrogol-digoxin
interaction study [30], 12 in a grapefruit juice-digoxin interaction study [2], and 13 in a dipyridamole-
digoxin interaction study [39]. The three studies were performed in accordance with the Declaration
of Helsinki and its amendments. Protocols were approved by the Ethics Committee of the Pitié-
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Salpêtrière Hospital (CCPPRB), Paris, France, and written informed consent was obtained from all
subjects. The 3 studies took place in the same clinical unit under the supervision of the same research
team.
All subjects received a 0.5 mg oral dose of digoxin with a glass of water after an overnight fast.
Pharmacokinetic samples were obtained at times 15, 30, 45 minutes, 1, 1.5, 2, 4, 6, 8, 12, 24 and
48 hours after the dose for two of the studies [2, 39]. For the last study [30], samples were taken at
15, 30, 45 minutes, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 16, 24, 48 and 72 hours.
The three studies included 23 men and 9 women, with a mean age of 25.8±5.2 years (range
19-35). Patients were genotyped for two MDR1 polymorphisms, C3435T polymorphism in exon 26
and G2677T/A polymorphism in exon 21. In study [39], patients were genotyped prior to inclusion
to balance the genotypes for the C3435T polymorphism while in the 2 other studies, genotyping was
performed after inclusion. As a result, the genotypes of the 32 patients for this polymorphism included
10 TT (mutant homozygotes, 31%), 8 CT (heterozygotes, 25%) and 14 CC (wild-type homozygotes,
44%). G2677T/A genotyping revealed 12 GG (38%), 11 GT (34%), 7 TT (22%), 1 GA (3%) and 1
AA (3%) subjects, with a linkage disequilibrium between the two polymorphisms (Somer’s D’=0.72).
Digoxin was measured using a modified enzyme multiplied digoxin immunoassay (EMIT 2000,
Dade Behring, Calif., USA), with a quantification limit of 0.1 ng/ml. MDR1 C3435T and G2677T/A
genotypes were determined by TaqMan allelic discrimination. More details concerning the analytical
methods can be found in [38, 37].
Statistical methods
Pharmacokinetic model The pharmacokinetics of digoxin were described using a two-compartment
model [15] with first-order absorption and elimination, and an absorption time-lag, using the analyti-
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cal form of the model. We assumed a proportional variance model for the residual error. This model
included six parameters: ka, kel, Vc/F, Tlag and the two transfer rate constants k1,2 and k2,1. In-
terindividual variability was estimated for the first four parameters, with no covariance between them
(diagonal variance matrix Ω).
Denoting f the function describing this model, the statistical model for concentration yi j in indi-
vidual i at time ti j is:
yi j = f (θi, ti j)+ εi j (1)
θi denotes the vector of parameters for individual i and its components are assumed to follow a log-
normal distribution:
θi = θ0 eηi (2)
where ηi ∼ N (0,Ω) is the vector of individual random effects.
The residual errors εi j are assumed to be independent, with distribution N (0,σ2i j), where the
variance of the error is modelled using a proportional error model: σ2i j = σ2 f (θi, ti j)2.
The model for covariate effect describes the relationship between the individual pharmacokinetic
parameters and a given covariate. The effect of polymorphism in exon 26 on a component θ(k) of the
vector of parameters θ was modelled as:
θ(k)i = θ
(k)
0 (1+β(k)CT)CT (1+β(k)TT)T T eηi (3)
Thus, the expected value of θ(k)i is θ
(k)
0 for subjects with genotype CC, θ(k)0 (1 + β(k)CT) for subjects
with genotype CT and θ(k)0 (1 + β(k)TT) for subjects with genotype TT. This model was used for the
4 parameters with variability (ka, kel, Vc/F, Tlag). In the following, we will drop the superscript (k)
for simplicity. For each parameter in the model, there are 5 possible models for the gene-parameter
relationship: the full model with three classes as in equation 3 (denoted H1 in the following), three
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intermediate models with two classes that we denote H0a:{βCT = 0}, H0b:{βT T = 0} and H0c:{βCT −
βT T = 0} and the model with no gene effect H0:{βCT = βT T = 0}. In the following, we first illustrate
the three covariate selection approaches using the polymorphism in exon 26, then we apply these
methods considering all the available covariates.
Backward covariate selection using the Wald test One approach to select the covariate model
is to estimate the parameters of a full model and perform a significance test using the Wald statistics
to select which parameters should be kept in the model [26]. The advantage of this method is that
model selection is performed in one step, and that interactions between covariates are taken into
account in the estimation of the parameters. Given the model described in equation 3, we test if the
three parameters βCT , βT T and (βCT − βT T ) are significantly different from zero by comparing the
corresponding Wald statistics to the critical value of a χ2 with one degree of freedom.
A screening step is often performed to eliminate candidate covariates which have a very small
probability of influencing the parameters, to improve the estimation of the remaining parameters in
the model. We choose an arbitrary value of 0.25 as the significance threshold, and we eliminate the
covariates for which the p-values of the 3 tests corresponding to the 3 null hypotheses H0a, H0b and
H0c are higher than 0.25. This yields a simplified model where some parameters are modelled accord-
ing to model H1 and some parameters are the same regardless of the genotype. This step eliminates
relationships that are totally irrelevant from the model and increases the precision of estimation of the
other, possibly meaningful, parameters.
In the next stage, we estimate again the parameters and their standard errors using the simpli-
fied model. For each parameter modelled using H1, the p-values of the three Wald tests are used
to select the appropriate relationship, after correction for multiple tests by applying the Simes pro-
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cedure [35, 3]. This method allows to control the family-wise error rate for the three simultaneous
tests performed. For a given parameter, the final model for the gene-parameter relationship depends
on which hypotheses are rejected. For example, if H0a and H0c are simultaneously rejected for a
parameter, equation 3 simplifies to:
θi = θ0 (1+βCT)CT eηi (4)
This procedure leads to the final model.
Forward covariate selection using the log-likelihood ratio test Convergence problems and non-
identifiability may occurr when trying to estimate the parameters of a full model with many covariates.
The alternative is to build the model using forward selection. Different forms of this approach are used
in most studies using nonlinear mixed effect models [23, 17].
For forward selection, we start from a model without covariates (basic model) and compute em-
pirical Bayes estimates (EBE) of the individual parameters. One-way analysis of variance (ANOVA)
is used to test for a difference between the three genotypes for each parameter [23]. As previously,
we begin by a screening step: candidate relationships are selected as those where the p-value of the
ANOVA is less than 0.25. We then model the candidate relationships as in equation 3 one at a time,
starting with the most significant according to the LRT. We stop when none of the remaining rela-
tionships provide a significant improvement in the model according to a LRT. We then test for all
parameter-gene relationships the three submodels H0a, H0b and H0c using the LRT again, correcting
the p-values using the Simes procedure. The best model for the corresponding relationship is selected
as in the previous strategy, based on the p-values for the three corresponding tests.
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Covariate selection using the Bayesian Information Criterion We compared the two previous
selection methods with model selection using the Bayes Information criterion (BIC) given by:
BIC =−2LL+P log(ntot) (5)
where P is the number of parameters (fixed and variance) in the model and ntot is the total number of
observations.
The best model is defined as the model with the lowest BIC. For model selection using the BIC,
we also consider models close to the lowest BIC. From the definition of Bayes factor as a ratio of
posterior to prior odds used in Bayesian model selection, Raftery shows that the strength of evidence
of one model versus the other is limited when models are within 3 points of BIC while a larger
difference provides positive evidence [29, 18].
A practical problem is the number of models to test. For each parameter in the model, there are 5
possible models when considering the genotype for exon 26 alone. To test all possible combinations
for the 4 parameters with variability would require generating and fitting 625 models. Although tech-
nically feasible here, this would soon become impractical with more covariates or more parameters,
therefore we propose a simplified approach. In a first step, for each parameter, we keep the model with
the lowest BIC, as well as models within 3 points of BIC to the lowest. The model without covariate
(H0) is also added to this list of possible models. In a second step, we build combined models where
the possible models for one parameter are combined with each of the models for the other parameters.
We estimate the corresponding BIC, and the best model s selected as the model having the lowest BIC
overall. Again, we also examine models with BIC close to the lowest value.
Estimation method The parameters are estimated using maximum likelihood approaches. Be-
cause the regression function is nonlinear with respect to the random effects, the likelihood function
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has no closed form. The most commonly used estimation methods rely on approximations of the
likelihood function through first-order Taylor expansions, and have been implemented for instance in
the nlme package in R/Splus [27], and in the NONMEM software [34]. To avoid this approximation,
Bayesian approaches have been proposed which integrate the likelihood using Monte-Carlo Markov
chains (MCMC) [36]. An alternative approach is to consider random effects as missing data and to
use the EM algorithm [9]. An algorithm called SAEM has been recently developed using the EM
approach: stochastic approximation combined with MCMC methods to simulate the random effect in
the E-step provides a convergent algorithm and consistent estimates of the population parameters [8].
This method has better statistical properties since no linearisation is involved in the computation of
the likelihood and hence the statistical tests based on the results have better properties [20]. It has
also been recently applied in two applications, the study the pharmacokinetics of saquinavir in HIV
patients [21] and the modelling of the viral load decrease to compare two treatments in a clinical
trial [32].
The SAEM algorithm is implemented in the MATLAB language in the software MONOLIX, avail-
able on the author’s website (http://www.math.u-psud.fr/∼lavielle/monolix/logiciels.html). We used ver-
sion 1.1 of MONOLIX, in a Linux environment (Red Hat 9.0, GNU Fortran compiler), with MATLAB
version 7. The analysis of the results was handled using the R statistical and graphical environ-
ment [28]. MONOLIX provides an estimate of the parameters (fixed effects and variance of the random
effects) as well as an estimate of the estimation error via the Fisher information matrix [20].
The likelihood is computed by an importance sampling procedure [31]. Since a good estimate of
the log-likelihood was required to perform likelihood ratio tests, we used the average of five successive
estimations of the likelihood to obtain a more stable estimate.
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Model building The three strategies described above were applied to the digoxin data considering
the exon 26 polymorphism. We then performed the same analysis for exon 21. For the G2677T/A
polymorphism in exon 21, 5 different genotypes were found in the population (GG, GT, GA, TT and
TA). We performed first an analysis taking them all into account, and second an analysis where we
regrouped the mutant alleles, yielding 3 groups (group 1: GG, group 2: GT or GA, group 3: TT
or TA). The influence of the polymorphism in exon 21 was analysed first independently from the
results of the analysis including exon 26, then including the model developed for exon 26 alone. We
also considered the homozygous wild-type diplotype (combined genotype) CC-GG, combining the
GG genotype at position 2677 in exon 21 and the CC genotype at position 3435 in exon 26, versus
all other diplotypes. The functional haplotype has previously been shown to influence the AUC of
digoxin [16]. Other haplotype analyses were not performed since the number of subjects was too
small. Finally, full covariate analysis was performed; the following covariates were available in the
study in addition to gene effect: gender, age, weight, body mass index and smoking status. Renal
function was not evaluated in these subjects.
We examined the following plots to evaluate the goodness of fit of the final model provided by
each approach: scatterplots of predictions (population and individual) versus individual observations;
population weighted residuals versus predictions and versus independent variable (time); absolute
individual weighted residuals versus individual predictions. In addition, model validation was per-
formed using prediction distribution errors [5], which are computed as the quantiles of the obser-
vations in the predicted distribution. The predicted distribution for each observation was obtained
through 1000 simulations of the data set given the final model. The prediction distribution errors
were decorrelated as proposed in [5] to take into account the correlation induced by the multiple ob-
servations within one subject. If the model is adequate, the distribution of the prediction distribution
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errors is expected to follow a uniform distribution over the interval [0-1], and we used a Kolmogorov-
Smirnov test to test this assumption.
Results
Backward covariate selection using the Wald test A full model including the effect of exon 26
genotype on all parameters was fit. The volume of distribution was the only parameter for which at
least one of the p-value of the Wald tests for the gene effect was lower than 0.25. The results are
shown in figure 1: for each parameter, we show the estimate of βCT, βTT and the difference βCT−βTT
as well as the corresponding confidence interval. The horizontal line represents the expected value of
0 in the absence of effect. As seen from this figure, only βTT and βCT−βTT for parameter Vc/F were
found to be significantly different from zero using Wald tests.
The model was then re-run with only Vc/F, yielding the following estimates for the gene effects:
βCT = 0.065 (NS), βTT =−0.164 (p<0.01), βCT−βTT = 0.229 (p<0.02). A final model was therefore
run, including only a different Vc/F for TT subjects.
Forward covariate selection using the log-likelihood ratio test Figure 2 displays the empiri-
cal Bayes estimates of the four parameters with intraindividual variability (ka, kel, Vc/F and Tlag),
separated according to the genotype for exon 26. As with the Wald test, only Vc/F was found to
have a significant relationship with the MDR-1 polymorphism on exon 26 (p<0.017 according to the
ANOVA), the three other tests yielding p-values larger than 0.4. Including the full gene effect in the
model for Vc/F led to an improvement in the model (p=0.007 according to a LRT, df=2).
In the next and final stage, we then tested the three submodels versus H1 using LRT yielding
the following p-values: p=0.003 for H0a={βCT = 0}, p=0.29 for H0b={βT T = 0}, and p=0.049 for
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H0c={βCT −βT T = 0}. Using the Simes procedure, the final model selected was the model where TT
subjects have different Vc/F from the two other groups. For the effect of exon 26 polymorphism, the
model selected by this strategy was therefore the same as for the selection based on Wald tests.
Covariate selection using the Bayesian Information Criterion The selection for each parameter
separately yielded the following results: for Vc/F, the best model was a model with different popula-
tion mean for TT subjects; for the other parameters, the best model was a model without covariates
and there was no model within 3 points of BIC of the lowest model. The results are illustrated in
figure 3, which shows the BIC of the five models tested for each parameter. For each parameter, the
model with the lowest BIC is shown as a full circle.
The models were then combined, and again, the best model overall was here the model with
different population mean for Vc/F in TT subjects.
Final model For the analysis of exon 26 alone, the three methods led to the same final model, a
model where the carriers of the TT genotype have a different population mean for Vc/F.
The same analyses were done considering the genotype for exon 21. We found no significant
parameter-genotype relationship when considering the five genotype group for exon 21 but some
genotypes were present in few subjects, suggesting a lack of power. When regrouping the subjects
in three groups according to the number of mutant alleles, the estimate of the volume of distribution
was slightly lower in group 3 (TT or TA) versus the other groups (p<0.04). However, when the
model for exon 26 was taken into account, this relationship disappeared, showing that the difference
is accounted for by exon 26 because of the strong linkage between the two exons (Somers D’=0.72).
The three approaches presented above therefore gave the same results for the selection of genetic
covariates in the model.
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In addition, 11 subjects carried the CC-GG diplotype, and a slight difference was found between
the estimates of the volume of distribution for these patients when using a Wald test (p=0.045). How-
ever, the two other methods (BIC and EBE) did not pick this difference up.
In the final step, we then added the other covariates to the model. Because of the strong linkage
disequilibrium between the two exons, the full covariate model included only exon 26. Using the
Wald test approach, the final model included different population mean for Vc/F in TT subjects,
as previously, as well as smaller absorption time-lag in women. Using the LRT approach, a small
increase in Tlag (2.5%) was also found for smoking patients, but the size of the effect was not clinically
significant and thus the final model was the same as with the Wald approach. The BIC approach was
not implemented for the full covariate selection because of time constraints.
The parameter estimates and estimates of the standard errors are given in table I. The parameters
were all well estimated, with standard errors lower than 20% except for the two covariate effects, for
which it was less than 40%. The residual (intraindividual) error was also small (17%). In this model,
subjects with the TT genotype have a volume of distribution lower by 17% relative to carriers of at
least a C allele, and women have a 54% shorter absorption time relative to men. The within-subject
variability was largest for the absorption rate constant ka.
A plot of the concentrations of digoxin as a function of time for the three genotypes for exon 26
is shown in figure 4. Overlayed is the corresponding population predictions for the group. Diagnostic
graphs for this model are shown in figure 5. The two upper graphs show respectively the population
(left) and individual (right) predictions versus observed concentrations. The two bottom graphs show
the individual predictions for the first two subjects in the dataset. The graphs show a satisfactory fit,
and the absorption phase is well described. A slight underestimation can be seen around 24 hours, as
the model does not capture a small rebound at that time. We tested two alternative models, one with a
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double absorption phase and one assuming enterohepatic recycling, but both encountered numerical
difficulties and unphysiological estimates, and the bias in the model was not improved. Therefore,
the two-compartment model was kept. We performed model validation for the final model; using
prediction discrepancies, we did not reject the hypothesis that the data observed could have been
obtained under the model (NS, p=0.49) and considered the model to be adequately qualified.
Discussion
With the recent availability of cheaper genotyping methods, it is now possible to collect genetic
information related to drug transporters, metabolic complexes or receptor structure on a routine basis
in clinical trials or before a patient is given a new treatment. In pharmacokinetics (PK) and pharma-
codynamics (PD), the time course of drug concentrations or effects is described using models with
a small number of parameters, and pharmacogenetic data is being increasingly used to characterise
their variability. There are now reports of pharmacogenetics studies for a large variety of drug classes,
confirming the widespread interest and potential applications of pharmacogenetics.
The statistical analysis in these studies however is usually limited to using non-compartmental
approaches to study the influence of genotype on AUC, apparent clearance or maximum or trough
concentration. Only a few papers report the use of more sophisticated methods such as mixed effect
models or Bayesian analysis, despite the fact that these approaches can be more informative. They
can take advantage of sparse designs, which could be useful to design studies for screening genetic
factors or during therapeutic monitoring. Here we present the first pharmacokinetic population model
for digoxin including pharmacogenetics.
In this study, we used three different methods to explore the relationships between the pharma-
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cokinetic parameters and the genetic covariates: forward stepwise selection, Wald test-based selec-
tion, and criteria-based selection. Although in the present application, they led to the same final
model, the three methods all have different characteristics and strengths.
The tests for the three approaches are asymptotic, that is, they assume that the number of subjects
as well as the number of points per subject is large enough. All three methods require good estimates
of the likelihood, and the Wald test requires in addition good estimates of the standard errors. The
only approximation in the computation of the estimated standard errors of estimation involved in
SAEM lies in the asymptotic approximation applied to the finite dataset [20], so that we expect better
statistical properties of the tests based on estimates obtained by SAEM relative to more traditional
methods based on first-order linearisation such as are implemented in NONMEM [34] or in the library
nlme for R [28]. Indeed, the standard errors of estimation of the parameters estimated using the SAEM
software have been shown to be accurately predicted [33].
Genetic covariates (genotypes or haplotypes) are usually modelled as categorical covariates, ex-
cept for some genes such as CYP2D6 where a numeric variable representing the number of mutant
alleles has been used as the genetic covariate [19]. Categorical covariates bring specific challenges.
We need to estimate one parameter for each possible genotype and the number of possible covariate
models increases exponentially with the number of genotypes. Also, the dataset is often unbalanced,
with sometimes a very small number of patients for the rarer genotypes, which can generate problems
for parameter estimation.
Given these specific challenges, being able to select the covariate model in one step with the Wald
test is appealing, and has been proposed by Panhard [26]. All the potential relationships are included
in the model and a simultaneous estimation of the significance of all the parameters is provided. This
approach could be most interesting in sparse data settings where the empirical Bayes estimates (EBE)
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do not contain as much information as they do in our example where the pharmacokinetic sampling
was rich. The three methods described above can be applied regardless of the estimation method, and
have been used for instance in NONMEM [17] and nlme [26]. Using the new algorithm SAEM, we can
obtain good estimates of the parameters and their estimation error, allowing us to select the covariate
model by backwards deletion from a full model. Compared to the two other methods, the Wald
test requires an additional assumption, in that the confidence interval for the estimated parameters is
assumed to be symmetrical, which makes it less robust than the LRT.
The likelihood ratio test, by contrast, does not require any additional hypothesis beyond that of
the asymptotic. Stepwise inclusion is therefore the main method used for covariate model selection in
PK/PD models. However, it suffers from a number of known problems: inflation of type I error due to
multiple testing during the building process, selection bias, collinear variables and no guarantee that
the final model selected using these methods is the correct model [41]. Inflation of the type I error
is also inherent to the first-order linearisation of the log-likelihood used by NONMEM [7], while the
stochastic approximation of the log-likelihood performed by SAEM retains a type I error closer to the
nominal value, as shown in simulation studies [14]. Variants of stepwise methods include building
generalised additive models using the empirical Bayes estimates of a model without covariate [24],
however they do not address the issues mentionned above. An interesting combination of the LRT
approach and the Wald approach could be outlined as follows: first, build a full model with all poten-
tial covariates included, and keep as candidate covariates those for which the Wald test is significant;
finally, build the covariate model using LRT-based forward or backward selection from these candi-
date covariates. This would reduce the number of models to test in the selection while allowing for
combination of covariates to enter the model.
Finally, the advantage of criterion-based strategies lies in their systematic exploration of all possi-
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ble models. The use of model selection criteria such as AIC or BIC is more frequent in the Bayesian
litterature [29] and has solid theoretical background in information theory. In practice however, AIC
often proves anti-conservative and has been shown to be non-consistent [42], and here we use the
BIC. Criterion-based strategies have two main drawbacks. The first drawback is that the number
of possible models increases exponentially with the number of covariates, although we can simplify
the number of possible models by considering prior physiological knowledge to eliminate unlikely
parameter-genotype relationships. The second drawback is that there is no formal test of the relative
performance of two models. Kass and Raftery propose to use the difference in BIC as a measure of
the strength of evidence of one model versus another [18], but one can be left with several competing
models of similar strength using that approach.
In summary, despite known problems we recall here, stepwise selection strategies are less com-
putationally cumbersome than criteria-based selection, while more robust to poor estimations of the
standard errors than selection based on the Wald test. However, it can be useful to explore candi-
date relationships using this last method, especially in the presence of a large number of covariates,
because as shown here it can provide reliable estimates in one step and because effects due to a
combination of several covariates may be missed by stepwise approaches.
The strategies outlined in this work can be used for all types of covariates (demographic data,
clinical characteristics, biological measurements...), as well as for building the structural model.
Our main finding, the difference in volume of distribution found for TT subjects, explains the
higher AUC observed for these subjects in the previous non-compartmental analysis performed using
this data [38]. It can be interpreted as a higher bioavailability in TT subjects relative to CC or CT
subjects. This result should be confirmed in patients receiving digoxin, and probably does not warrant
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dose adjustment for digoxin, especially considering the high variability in absorption. A possible ex-
ception would be to adjust dosage in certain populations such as elderly patients or patients receiving
other comedications. The proportion of digoxin-treated patients experiencing therapeutic drug moni-
toring has been shown to increase with the number of PgP inhibitors received [11], which could make
it useful to determine the genotype governing PgP activity [12].
In conclusion, we modelled the pharmacokinetics of digoxin including pharmacogenetic data,
using nonlinear mixed effect models. Our main finding was that carriers of the TT genotype for the
C3435T polymorphism in exon 26 of the MDR-1 gene have lower apparent volume of distribution.
Several methods can be used to test for genetic effects. In addition to the usual stepwise selection
method, we recommend using the Wald test to screen candidate covariates.
Acknowledgments
This study complies with the current laws of France, where they were performed, and the protocols
were approved by the Ethics Committee of the Pitié-Salpêtrière Hospital (CCPPRB), Paris, France.
20
H
AL author m
anuscript    inserm
-00146888, version 1
REFERENCES
[1] Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, et al.
(2003) Association of the Multidrug Resistance-1 gene single-nucleotide polymorphisms with
the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 14: 1889–
1896
[2] Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, et al. (2001) Effect of
grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 70: 311–316
[3] Benjamini Y, Hochberg B (1995) Controlling the false discovery rate: a practical and powerful
approach to multiple testing. JRSS B 57: 289–300
[4] Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R, et al. (2004)
MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant
recipients. Transplantation 78: 21–25
[5] Brendel K, Comets E, Laffont C, Laveille C, Mentré F (2006) Metrics for external model eval-
uation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23:
2036–49
[6] Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. (2002) Therapeu-
tic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor
FcgammaRIIIa gene. Blood 99: 754–758
[7] Comets E, Mentré F (2001) Evaluation of tests based on individual versus population modelling
to compare dissolution curves. J Biopharm Stat 11: 107–123
21
H
AL author m
anuscript    inserm
-00146888, version 1
[8] Delyon B, Lavielle M, Moulines E (1999) Convergence of a stochastic approximation version
of the EM algorithm. Ann Stat 27: 94–128
[9] Dempster A, Laird N, Rubin D (1977) Maximum likelihood from incomplete data via the EM
algorithm. JRSS B 39: 1–38
[10] Diasio R, Johnson M (2000) The role of pharmacogenetics and pharmacogenomics in cancer
chemotherapy with 5-fluorouracil. Pharmacology 61: 199–203
[11] Englund G, Hallberg P, Artursson P, Michaelsson K, Melhus H (2004) Association between
the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on
therapeutic drug monitoring. BMC Med 2: 8
[12] Ensom M, Chang T, Patel P (2001) Pharmacogenetics: the therapeutic drug monitoring of the
future? Clin Pharmacokinet 40: 783–802
[13] Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G (2002) Tumor necrosis
factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and
severe rheumatoid arthritis. J Rheumatol 29: 1847–1850
[14] Girard P, Mentré F (June 16-17 2005) A comparison of estimation methods in nonlinear mixed
effects models using a blind analysis. Population Approach Group in Europe (Abstract 384),
Pamplona (Spain)
[15] Hornestam B, Jerling M, Karlsson MO, Held P (2003) Intravenously administered digoxin in
patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis
based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol 58: 747–755
22
H
AL author m
anuscript    inserm
-00146888, version 1
[16] Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al. (2002) Modulation of steady-
state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther
72: 584–594
[17] Jonsson E, Karlsson M (1998) Automated covariate model building with NONMEM. Pharm
Res 15: 1463–1468
[18] Kass R, Raftery A (1995) Bayes factors. J Am Stat Assoc 90: 773–795
[19] Kirchheiner J, Heesch C, Bauer S, Meisel C, Seringer A, Goldammer M, et al. (2004) Impact of
the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics
and pharmacodynamics. Clin Pharmacol Ther 76: 302–312
[20] Kuhn E, Lavielle M (2005) Maximum likelihood estimation in nonlinear mixed effects models.
Comput Stat Data Analysis 49: 1020–1038
[21] Lavielle M, Mentré F (2006) Estimation of population pharmacokinetic parameters of saquinavir
in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn, in press
[22] Ludden T, Beal S, Sheiner L (1994) Comparison of the Akaike Information Criterion, the
Schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 22:
431–445
[23] Maitre P, Buhrer M, Thomson D, Stanski D (1991) A three-step approach combining Bayesian
regression and NONMEM population analysis: application to midazolam. J Pharmacokinet
Biopharm 19: 377–378
23
H
AL author m
anuscript    inserm
-00146888, version 1
[24] Mandema J, Verotta D, Sheiner L (1992) Building population pharmacokinetic-
pharmacodynamic models. I. Models for covariate effects. J Pharmacokin Biopharm 20:
511–528
[25] McLeod H, Yu J (2003) Cancer pharmacogenomics: SNPs, chips, and the individual patient.
Cancer Invest 21: 630–640
[26] Panhard X, Mentré F (2005) Evaluation by simulation of tests based on non-linear mixed-effects
models in pharmacokinetic interaction and bioequivalence cross-over trials. Stat Med 10: 1509–
1524
[27] Pinheiro J, Bates D (2000) Mixed-Effects Models in S and S-PLUS. Springer-Verlag, New York
[28] R Development Core Team (2004) R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria
[29] Raftery A (1996) Markov chain Monte Carlo in practice. Chapman & Hall, London
[30] Ragueneau I, Poirier J, Radembino N, Sao A, Funck-Brentano C, Jaillon P (1999) Pharma-
cokinetic and pharmacodynamic drug interactions between digoxin and macrogol. Br J Clin
Pharmacol 48: 453–456
[31] Robert C, Casella G (1999) Monte Carlo Statistical Methods. Springer-Verlag, New York
[32] Samson A, Lavielle M, Mentré F (2006) Extension of the SAEM algorithm to left-censored
data in nonlinear mixed-effects model: Application to HIV dynamics model. Comput Stat Data
Analysis 51: 1562–74
24
H
AL author m
anuscript    inserm
-00146888, version 1
[33] Samson A, Mentré F, Lavielle M (September 26-27, 2005) Using SAEM, a new maximum
likelihood estimation method in nolinear mixed-effects models, for comparison of longitudinal
responses. 5th International Meeting of Statistical Methods in Biopharmacy, Paris (France)
[34] Sheiner L, Beal S (1998) NONMEM Version 5.1. University of California, NONMEM Project
Group, San Francisco
[35] Simes R (1986) An improved Bonferroni procedure for multiple tests of significance. Biometrika
73: 751–754
[36] Spiegelhalter DJ, Thomas A, Best NG (2000) WinBUGS version 1.3 User Manual. Imperial
College, London, United Kingdom
[37] Verstuyft C, Morin S, Yang J, Loriot MA, Barbu V, Kerb R, et al. (2003) A new, rapid and robust
genotyping method for CYP2C9 and MDR1. Ann Biol Clin (Paris) 61: 305–309
[38] Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, et al. (2003) Digoxin
pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 58: 809–812
[39] Verstuyft C, Strabach S, El Morabet H, Kerb R, Brinkmann U, Dubert L, et al. (2003) Dipyri-
damole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 73:
51–60
[40] Wählby U, Bouw M, Niclas Jonsson E, Karlsson M (2002) Assessment of type I error rates for
the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn 29: 251–269
25
H
AL author m
anuscript    inserm
-00146888, version 1
[41] Wählby U, Niclas Jonsson E, Karlsson M (2002) Comparison of stepwise covariate model build-
ing strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 4:
E27
[42] Yang Y (2005) Can the strengths of AIC and BIC be shared? A conflict between model identi-
fication and regression estimation. Biometrika 92: 937–950
26
H
AL author m
anuscript    inserm
-00146888, version 1
Appendix
The SAEM algorithm is implemented the MATLAB language in the software MONOLIX, available on
the author’s website (http://www.math.u-psud.fr/∼lavielle/monolix/logiciels.html). We used MONOLIX
version 1.1.
The dataset was prepared in R as a two-dimensional array, with columns representing subject
ID, time and observed concentrations. A column representing the dose was also added (with the
same value at all times and for all subjects). To code for the categorical covariates representing the
genotypes of MDR1, we used dummy variables. For example, to code for the exon 26 polymorphism,
we defined 3 dummy variables, one with value 1 for the subjects with CC genotype and 0 for the
other two genotypes, one with value 1 for the subjects with CT genotype and 0 otherwise, and one
with value 1 for the subjects with TT genotype and 0 otherwise. Each dummy variable was entered
as an additional column in the dataset. Exemples of datasets used with MONOLIX are included in the
Zip file containing the program.
The following code was used to define the pharmacokinetic model (lines beginning with the sym-
bol % are comments), using the explicit analytical equation:
function [f,g]=dig_funct(phi,x,id);
%%%%%%%%%%%%%%%%%%%%%%%
d=x(:,1,:);
t=x(:,2,:);
%%%%%%%%%%%%%%%%%%%%%%%
ka=exp(phi(id,1,:));
ke=exp(phi(id,2,:));
V=exp(phi(id,3,:));
Tlag=exp(phi(id,4,:));
k12=exp(phi(id,5,:));
k21=exp(phi(id,6,:));
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%%%%%%%%%%%%%%%%%%%%%%%
bet=(ke+k12+k21-sqrt((k12+k21+ke).^2-4*k21.*ke))./2;
alp=(k21.*ke)./bet;
f=d.*ka./V.*(((k21-ka)./((alp-ka).*(bet-ka))).*exp(-ka.*(t-Tlag))+...
((k21-alp)./((ka-alp).*(bet-alp))).*exp(-alp.*(t-Tlag))+...
((k21-bet)./((ka-bet).*(alp-bet))).*exp(-bet.*(t-Tlag)));
g=f;
The program MONOLIX is run from within MATLAB. A window opens in which the user specifies
the dataset, the model function and the number of covariates to include in the analysis. In our analysis,
the variance-covariance matrix was set to diagonal and the variance for parameters k1,2 and k2,1 was
set to 0. The covariate model was also specified via the graphical interface as a linear combination of
the dummy covariates defined above.
Version 1.1 of the software requires some tuning of the numerical procedure to ensure convergence
of the Markov chain during the stochastic approximation step (see the user manual on the website).
We used the following sequence of four stepsizes in the algorithm:

a1 = 0 during K1=500 iterations
a2 = 0.5 during K2=100 iterations
a3 = 0.8 during K3=100 iterations
a4 = 1 during K4=2000 iterations
(6)
The output from MONOLIX consists in a series of graphs as well as a table of parameter estimates
with their associated standard errors. Hypothesis testing opens a new window in which the two models
compared are specified and the corresponding criteria (AIC, BIC, log-likelihood) are shown after the
fit of each model is performed. Empirical Bayes Estimates (EBE) of the individual parameters are
obtained as the mean of the posterior distribution and the standard errors on these parameters (the
standard deviations of the posterior distribution) are also reported.
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LEGENDS FOR FIGURES
Figure 1: Estimates of the genetic fixed effect for the different parameters in the model.
Figure 2: Empirical Bayes estimates of ka, kel, Vc/F and Tlag with the model without covariate.
Figure 3: BIC for the five models tested for each parameter: basic model (no gene effect), submodels
with βCT = βTT, βCC = βTT or βCC = βCT, full model with βCC and βTT.
Figure 4: Concentration versus time data for digoxin, for the three genotype classes for exon 26 poly-
morphism (in log-scale). Overlayed is the line corresponding to the predictions using the population
parameters in each group, for men.
Figure 5: Goodness of fit plots for the final model. Top: population predicted concentrations versus
observed concentrations (left); individual predicted concentrations versus observed concentrations
(right). Bottom: predicted concentrations (line) overlayed on observed concentrations (dots) for the
first man (left) and the first woman (right) in the dataset.
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Tables
Table I : Estimates of the population pharmacokinetic parameters for the final model.
Parameter Population mean (SE as %) Variability as % (SE on ω2 as %)
ka (hr−1) 3.15 (20) 85 (32)
kel (L.hr−1) 0.09 (6) 17 (63)
Vc/F (L) 172.70 (5) 15 (30)
βV,TT (-) -0.17 (31) -
Tlag (hr) 0.21 (8) 28 (42)
βTlag,women (-) -0.43 (27) -
k1,2 (hr−1) 0.32 (7) -
k2,1 (hr−1) 0.10 (7) -
σ (%) 0.18 (4) -
† p=0.001 according to Wald test
†† p=0.0002 according to Wald test
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